
2022
东方百泰 Company profile
北京东方百泰生物科技股份有限公司成立于2011年,坐落于亦庄经济技术开发区,公司总占地面积6万平方米,是国内的抗体药物研发、生产及销售企业。公司产品类别主要以全人源单抗、人源化单抗、双特异抗体、抗体融合蛋白、治疗性疫苗等为主,适应症涵盖恶性肿瘤、糖尿病、自身免疫性疾病(类风湿性关节炎、银屑病、强直性脊柱炎等)、高血脂症、哮喘等众多高发性疾病。
公司拥有上百人专业抗体研发团队,布局了20多余项研发管线,先后承担了多项国家“重大新药创制”、部委专项课题和“863”计划等十一五、十二五重点项目。东方百泰始终将"品质与创新"作为企业的永恒追求。公司始终坚持以创新为企业发展的源动力,注重产业转化,其位于北京亦庄新的大规模产业基地正在建设中,总投资将达15亿,其中一期占地30亩,届时将建成一条3*3000L,符合中国、美国GMP要求的先进水平的抗体生产线。预计2022年投入使用。
DONGFANG BAITAI Company profile
Located in Yizhuang’s Economic and Technological Development Area with a total area of about 60000 square meters, Eastern Biotech was founded in 2011 and became a leading biomedical R&D, production and sales company in China. The company's product categories include full human monoclonal antibody, humanized monoclonal antibody, bispecific antibody, antibody fusion protein, therapeutic vaccine, to name a few that target prevalent diseases such as malignant tumors, diabetes, autoimmune diseases (rheumatoid arthritis, psoriasis, ankylosing spondylitis, etc.), ophthalmic diseases, respiratory diseases, etc.
Here at Beijing Eastern Biotech, we have a biological drug research and development team with more than 100 people who laid out more than 20 research and development pipelines, obtained 7 approval documents for clinical trials of new drugs, and are conducting clinical trial research. We have undertaken a number of national "major new drug development", special projects of various ministries and commissions, the "863" plan and other key projects such as the 11th and 12th Five Year Plan. We always hold "quality and innovation" as the eternal pursuit and source of power for the company and remain attentive towards changes in the industry.
Our new large-scale industrial base in Yizhuang, Beijing, is under construction with a total investment of 1.5 billion yuan. The first phase covers an area of 30 mu (about 4.9 acres) where a 3 * 2000L mammal batch cultivation production line will be built. It will meet the advanced requirements of China and the United States GMP, and it is expected to be officially put into use in 2023.
Dongfang Baitai Biopharmaceutical Co., Ltd. (or Eastern Pharmaceutical), a subsidiary of Eastern Biotech, is one of the earliest companies to be engaged in antibody drug development in China. Its core product Tai Xin Sheng® (nimotuzumab) is the first humanized monoclonal antibody drug targeting nasopharyngeal cancer China, and it has a therapeutic effect on many other cancers such as: head and neck, pancreatic, breast, glioma, non-small cell lung, etc. It was added to the Chinese Pharmacopoeia in 2015 and the national medical insurance in 2017, significantly contributing to the field of biomedical antibodies in China!
Eastern Biotech has been successively awarded the titles of "Beijing Engineering Laboratory of Antibody Project" and "Beijing Engineering Research Center of Antibody Drugs". It is not only the "Beijing International Science and Technology Cooperation Base for New Antibody and Therapeutic Protein Drugs", but also the "National International Science and Technology Cooperation Base for Advanced Technologies of New Antibody and Therapeutic Protein Drugs". We have successively established a "Postdoctoral Scientific Research Workstation" a "Academician Expert Workstation", and we are certified by the national intellectual property management system and the International Organization for Standardization (ISO 9000).
2011year
Date of establishment
20+
R&D pipeline layout
50%+
Percentage of doctors and masters
100+
Invention patent
3*2000L
Large scale production line
The enterprise culture
Corporate mission
Gather the power of biomedicine
Create a healthy life for human beings
Corporate philosophy
The Doctors
The conscience of the druggist
Corporate Vision
Protect life and health
Become an international first-class pharmaceutical group with leading technology
Core values
Responsibility: responsibility, integrity and perseverance
Quality: profession, reputation and pursuit
Innovation: exploration, attitude, change
Health: spirit, life, care
The development course
2022 |
● Dongfang Baitai has been certified by ISO9000(Quality Management system certification, environmental management system certification and Occupational health and safety management system certification).
2021 |
● Top 100 Private Enterprises in Beijing 2020
● Dongfang Baitai has been recognized as "Beijing specialized in special and new small giant Enterprise".
● Dongfang Baitai won the title of "China's New Pharmaceutical Innovation Force in 2021".
● JY025 won the "China Patent Excellence Award".
● Dongfang Baitai won the "First Prize of Independent Innovation Achievements of Capital Employees in 2020".
2020 |
● Dongfang Baitai was recognized as "Beijing Enterprise Technology Center"
● Dongfang Baitai was recognized as "Municipal Employee Innovation Studio for bio-drug Development of Major Diseases".
● Dongfang Baitai was recognized as "Municipal Employee Innovation Studio for bio-drug Development of Major Diseases".
● JY016 won the "14th Beijing Innovation Competition Public Innovation Award"
● JY09 won the 21st China Patent Silver Award
● Dongfang Baitai was recognized as "Beijing Intellectual Property Demonstration Unit"
●"Beijing Dongfang Baitai Biotechnology Co., LTD." completed the share reform and changed its name to "Beijing Dongfang Baitai Biotechnology Co., LTD."
2019 |
●Dongfang Baitai is recognized as the "Home of Science and Technology Workers"
● Dongfang Baitai won the Second Prize of "2018 Capital Employees' Independent Innovation Achievements"
● Dongfang Baitai won the second Prize of "2019 Maker China Beijing smes Innovation and Entrepreneurship Competition" (Enterprise Group)
● Dongfang Baitai was identified as "Industrial Enterprise Intellectual Property Application Pilot Enterprise"
2018 |
● Dongfang Baitai won the "National Intellectual Property Management System Certification"
● JY025 has been approved for clinical trials
● Antibody drug research and development and industrialization base engineering capping
2017 |
● Academician expert Research station was officially established
● The post-doctoral research station was officially established
● JY09 won the first prize of "2016 Capital Employees Independent Innovation Achievement"
● JY028(AMD) has been approved for clinical trials
● Antibody drug research and development and industrialization base project is under construction
● JY026 has been approved for clinical trials
● JY028 has been approved for clinical trials
2016 |
● Dongfang Baitai has been recognized as the "International scientific and Technological Cooperation Base for New Antibody and therapeutic protein Drug Frontier Technology".
● "JY09" won "T100 New Products and New Technology"
● "JY09" won "T100 New Products and New Technology"
● "JY09" has been approved for clinical trials
2015 |
● The holding subsidiary "Baitai Biological Pharmaceutical Co., LTD." marks the 15th anniversary of its establishment
● Dongfang Baitai was recognized as the "Innovation Studio for Biological drug Development Staff".
2014 |
● Dongfang Baitai was recognized as "Zhongguancun High-tech Enterprise"
● Dongfang Baitai was recognized as "Beijing International Science and Technology Cooperation Base for New Antibody and Therapeutic Protein Drug Frontier Technology".
● Dongfang Baitai won the "Patent Pilot Certificate"
2013 |
● Dongfang Baitai was recognized as "Beijing Engineering Research Center for Antibody Drugs".
2011 |
● Dongfang Baitai was identified as "Beijing Engineering Laboratory of Antibody Engineering"
● Dongfang Baitai was recognized as "Beijing Genetic Engineering Antibody Drug Engineering Technology Research Center"
● Beijing Dongfang Baitai Biotechnology Co., LTD was established
2008 |
● "Beijing Jingyi Taixiang Technology Development Co., LTD." was restructured to prepare for the establishment of "Beijing Dongfang Baitai Biotechnology Co., LTD."
企业文化 The enterprise culture
使命:凝聚生物医药力量,创享人类生活健康
理念:医者仁心,药者良心
愿景:守护生命健康,成为技术的制药集团
核心价值观
责任: 担当、诚信、坚守,乃企业立足之根本。
品质: 专业、信誉、追求,乃企业永恒之基石。
创新: 探索,态度,变革,乃企业长青之保障。
健康: 精神,生命,关爱,乃企业奋斗之目标。
发展历程 The development course
Follow us
Follow the official WeChat official account
Or search "Oriental Baitai"
More exciting waiting for you!
Address: No. 2, Rongjing East Street, Beijing Economic and Technological Development Zone
Tel.: 010-51571019
Email: ebt@east-bt.com
Copyright 2021 Beijing Dongfang Baitai Biotechnology Co., Ltd SEO 京ICP备2023010711号-1